Although pre-clinical studies of RAGE inhibition in AD strengthen the fact that RAGE might represent a potential therapeutic target, future pre-clinical and clinical studies are warranted to evaluate the safety and therapeutic efficacy of RAGE antagonists against AD [22]. The gene discussed is AGER; the disease is Alzheimer disease.